Lucid Diagnostics (NASDAQ:LUCD) Director Dennis Matheis Buys 245,000 Shares of Stock

Lucid Diagnostics Inc. (NASDAQ:LUCD) Director Dennis Matheis purchased 245,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average cost of $1.00 per share, with a total value of $245,000.00. Following the completion of the purchase, the director owned 1,033,443 shares in the company, valued at $1,033,443. This trade represents a 31.07% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Lucid Diagnostics Stock Performance

LUCD stock opened at $1.00 on Friday. Lucid Diagnostics Inc. has a 12 month low of $0.90 and a 12 month high of $1.70. The company has a 50-day moving average price of $1.16 and a 200 day moving average price of $1.18. The stock has a market cap of $203.07 million, a PE ratio of -2.13 and a beta of 1.10.

Lucid Diagnostics (NASDAQ:LUCD) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). The company had revenue of $1.26 million for the quarter, compared to analysts’ expectations of $1.38 million. Sell-side analysts forecast that Lucid Diagnostics Inc. will post -0.22 EPS for the current year.

Institutional Investors Weigh In On Lucid Diagnostics

Several large investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE boosted its position in Lucid Diagnostics by 25.9% in the 1st quarter. Bank of America Corp DE now owns 88,527 shares of the company’s stock valued at $102,000 after buying an additional 18,212 shares during the period. Sunbelt Securities Inc. lifted its position in shares of Lucid Diagnostics by 134.4% in the 1st quarter. Sunbelt Securities Inc. now owns 900,013 shares of the company’s stock worth $1,035,000 after purchasing an additional 516,014 shares during the period. XML Financial LLC lifted its position in shares of Lucid Diagnostics by 24.8% in the 1st quarter. XML Financial LLC now owns 223,195 shares of the company’s stock worth $257,000 after purchasing an additional 44,400 shares during the period. XTX Topco Ltd purchased a new stake in shares of Lucid Diagnostics in the 4th quarter worth approximately $246,000. Finally, Millennium Management LLC purchased a new stake in shares of Lucid Diagnostics in the 4th quarter worth approximately $168,000. 74.01% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

LUCD has been the subject of a number of recent analyst reports. Maxim Group dropped their price target on shares of Lucid Diagnostics from $3.00 to $2.00 and set a “buy” rating for the company in a research note on Friday, May 15th. BTIG Research reaffirmed a “buy” rating and set a $2.50 price target on shares of Lucid Diagnostics in a research note on Friday, May 15th. Wall Street Zen cut shares of Lucid Diagnostics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lucid Diagnostics in a research report on Wednesday, May 6th. Finally, Ascendiant Capital Markets boosted their price objective on shares of Lucid Diagnostics from $8.25 to $9.00 and gave the company a “buy” rating in a research report on Thursday, April 9th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $4.13.

About Lucid Diagnostics

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.